Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy

Circulation

Volumn 124, Issue 20, 2011, Pages 2202-2207

  Raal, Frederick J ^a   Pilcher, Gillian J ^a   Panz, Vanessa R ^a   Van Deventer, Hendrick E ^b   Brice, Brigitte C ^c   Blom, Dirk J ^c   Marais, A David ^c  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

hypercholesterolemia, familial; lipid lowering therapy; mortality; statins

Indexed keywords

ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; HAZARD RATIO; HUMAN; ILEUM BYPASS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMAPHERESIS; PORTOCAVAL SHUNT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SOUTH AFRICA;

ADOLESCENT; ADULT; CHILD; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 81355160365     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.042523     Document Type: Article

References (32)

1. Goldstein JL, Hobb HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001: 2863-2913.
2. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111: 1795-1803. (Pubitemid 38057721)
3. Seftel HC, Baker SG, Sandler MP, Forman MB, Joffe BI, Mendelsohn D, Jenkins T, Meiny CJ. A host of hypercholesterolaemic homozygotes in South Africa. BMJ. 1980;281:633-636. (Pubitemid 10051766)
4. Gevers W. Three mutations that cause familial hypercholesterolemia in Afrikaners identified: a milestone in South African medicine. S Afr Med J. 1989;76:393-394. (Pubitemid 20003455)
5. Brown MS, Goldstein JL. Lowering LDL: not only how low, but how long? Science. 2006;311:1721-1723.
6. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
7. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes R, Collins R; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
8. Raal FJ, Pilcher GJ, Illingworth DR, Pappu AS, Stein EA, Laskarzewski P, Mitchel YB, Melino MR. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia. Atherosclerosis. 1997;135: 244-256.
9. Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black DM. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolemia. Atherosclerosis. 2000;150:421-428. (Pubitemid 30336555)
10. Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Palmer M, Wilp-shaarf W. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolemia. Atherosclerosis. 2008;197:400-406. (Pubitemid 351284477)
11. Gagné C, Gaudet D, Bruckert E; for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105: 2469-2475. (Pubitemid 34568966)
12. Leiden Open (source) Variation Database (LOVD). The low-density lipoprotein receptor (LDLR) gene in familial hypercholesterolemia. http://www.ucl.ac.uk/fh. Accessed May 6, 2011.
13. Heath KE, Gahan M, Whitall RA, Humphries SE. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolemia: update, new features and mutational analysis. Atherosclerosis. 2001;154: 243-246. (Pubitemid 32008586)
14. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
15. Kotze MJ, Theart L, Callis M, Peeters AV, Theart R, Langenhoven E. Nonradioactive multiplex PCR screening strategy for the simultaneous detection of multiple low density lipoprotein receptor gene mutations. PCR Methods Appl. 1995;4:352-356.
16. Rubinsztein DC, Coetzee GA, Marais AD, Leitersdorf E, Seftel HC, van der Westhuizen DR. Identification and properties of the proline 664-leucine mutant LDL receptor in South Africans of Indian origin. J Lipid Res. 1992;33:1647-1655.
17. Boren J, Ekstrom U, Agren B, Nilsson-Ehle P, Innerarity TL. The molecular mechanism for the genetic disorder familial defective apolipo-protein B 100. J Biol Chem. 2001;275:9214-9218.
18. Abera AB, Marais AD, Raal FJ, Leisegang F, Jones S, George P, Henderson HE. Autosomal recessive hypercholesterolemia: discrimination of ARH protein and LDLR function in the homozygous FH phenotype. Clin Chem Acta. 2007;378:33-37. (Pubitemid 46241057)
19. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE; on behalf of the Simon Broome Familial Hyperlipi-daemia Register Group. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercho-lesterolemia: a prospective registry study, Eur Heart J, 2008, 29, 2625-2633.
20. Versmissen J, Oosteveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, Heeringa J, Wittemen JC, Lansberg PJ, Kastelein JJP, Sijbrands EJG. Efficacy of statins in familial hypercholesterolemia: a long term cohort study. BMJ. 2008:337:a2423.
21. Slack J. Risks of ischaemic heart disease in familial hyperlipidaemic states. Lancet. 1969;2:1380-1382.
22. Deckelbaum RJ, Lees RS, Small DM, Hedberg Se, Grundy SM. Failure of complete bile diversion and oral bile acid therapy in the treatment of homozygous hypercholesterolemia. N Engl J Med. 1977;296:465-470. (Pubitemid 8038307)
23. López-Santamaria M, Migliazza L, Gamez M, Murcia J, Diaz-Gonsalez M, Camarena C, Hierro L, De la Vega A, Frauca E, Diaz M, Jara P, Tovar J. Liver transplantation in patients with homozygotic hypercholesterol-emia previously treated by end-to-side portacaval shunt and ileal bypass. J Pediatr Surg. 2000;35:630-633. (Pubitemid 30181048)
24. Thompson GR. Lipoprotein apheresis. Curr Opin Lipidol. 2010;21: 487-491.
25. Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, Takegoshi T; Hokuriku FH-LDL-Apheresis Study Group. Long-term efficacy of low-density lipoprotein apheresis in coronary heart disease in familial hypercholesterolemia. Am J Cardiol. 1998;82:1489-1495. (Pubitemid 29006472)
26. Awan Z, Alrasadi K, Francis GA. Vascular calcifications in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2008;28: 777-785. (Pubitemid 351651345)
27. Marais AD, Blom DJ, Firth JC. Statins in homozygous familial hyper-cholesterolemia. Curr Atheroscler Rep. 2002;4:19-25
28. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;144: 1383-1389.
29. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; for the PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-235.
30. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006.
31. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148-156. (Pubitemid 46089675)
32. Stein EA. Other therapies for reducing low-density lipoprotein cholesterol: medications in development. Endocrinol Metab Clin N Am. 2009;38:99-119.